Pyrintegrin
Based on 6 publication(s) in Google Scholar
Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.71%
- CAS No.: 1228445-38-2
- 화학식: C23H25N5O3S
- 분자량:451.54
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pyrintegrin
More- Nat Nanotechnol. 2026 Jun;21(6):880-891. [Abstract]
- Biomaterials. 2024 Mar:305:122462. [Abstract]
- Mol Ther. 2023 Jun 7;31(6):1846-1856. [Abstract]
- Phytother Res. 2026 Jul;40(7):4660-4675. [Abstract]
- Matrix Biol Plus. 2024 May 17:22:100148. [Abstract]
- Biomed Pharmacother. 2023 Oct:166:115394. [Abstract]
Customer Validation & Images
-
IF
-
WB
-
Cell Migration/Invasion Assay
-
Bio/Physico-chemical Assay
-
IF
Biological Activity
β1-integrin[2]
Pyrintegrin (0-10 μM; 1 hour; hASCs) treatment inhibits BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner (IC50 of 1.14 μM)[1].
In vitro, Pyrintegrin stimulats human adipose stem/progenitor cells (hASCs) to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), with differentiated cells increasingly secreting adiponectin, leptin, glycerol and total triglycerides. Pyrintegrin attenuates Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation[1].
Treatment with Pyrintegrin prevents damage-induced decreases in F-actin stress fibers, focal adhesions, and active β1-integrin levels in cultured cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human adipose stem/progenitor cells (hASCs)[2]
-
Concentration:0 µM, 0.2 µM, 0.5 µM, 1 µM, 2 µM, 5 µM, 10 µM
-
Incubation Time:1 hour
-
Result:Inhibited BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner.
In rats, Pyrintegrin reduces peak proteinuria caused by puromycin aminonucleoside-induced nephropathy[2].
Pyrintegrin induces postnatal adipose tissue formation in vivo of transplanted adipose stem/progenitor cells (ASCs) and recruited endogenous cells. In vivo, Pyrintegrin-treated human adipose stem/progenitor cells (ASCs) in 3D-bioprinted scaffolds, when transplanted in the dorsum of athymic mice, yielded ectopically formed adipose tissue that expressed human PPARγ. Remarkably, Pyrintegrin-adsorbed collagen gel implanted in the inguinal fat pad promoted adipogenesis formed by host endogenous cells, suggesting its ability to induce in situ adipogenesis without the need for cell transplantation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female wild type C57BL/6J mice (10-week-old) injected with LPS[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; once
-
Result:Provided a significant protection for these animals from LPS-induced proteinuria and foot processe (FP) effacement.
Chemical Information
-
CAS No. 1228445-38-2
-
Appearance Solid
-
분자량 451.54
-
화학식 C23H25N5O3S
-
Color Off-white to light yellow
-
SMILES
O=S(C1=CC=C(NC2=NC=CC(N3CCCC4=C3C=CC(O)=C4)=N2)C=C1)(NCC5CC5)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Nat Nanotechnol
2026 Jun;21(6):880-891. PMID: 42286217 -
Biomaterials
FAK-p38 signaling serves as a potential target for reverting matrix stiffness-modulated liver sinusoidal endothelial cell defenestration. [Abstract]2024 Mar:305:122462. PMID: 38171118
Pyrintegrin purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Mar:305:122462. [Abstract]
Representative immunostained images of p-FAK (red) in LSECs cultured on a coverglass-bottomed dish with Pyrintegrin (0.5 μM; 20 h) treatment with the relevant quantitative analysis of MFI (n =30 images from 3 biological replicates). DMSO served as a vehicle control.
-
Mol Ther
ROCK inhibition enhanced hepatocyte liver engraftment by retaining membrane CD59 and attenuating complement activation. [Abstract]2023 Jun 7;31(6):1846-1856. PMID: 36860134 -
Phytother Res
Atractylenolide I Blocks Lung Metastasis of Triple-Negative Breast Cancer by Inhibiting SPP1-Mediated Extracellular Matrix Signaling Pathway. [Abstract]2026 Jul;40(7):4660-4675. PMID: 42138273 -
Matrix Biol Plus
Extracellular matrix stiffness mediates insulin secretion in pancreatic islets via mechanosensitive Piezo1 channel regulated Ca2+ dynamics. [Abstract]2024 May 17:22:100148. PMID: 38803329
Pyrintegrin purchased from MedChemExpress. Usage Cited in: Matrix Biol Plus. 2024 May 17:22:100148. [Abstract]
Western blot quantification of RhoA in Min6 cells untreated (-) and treated (+) with Pyrintegrin (5 μM; 1 h), a β1 integrin agonist (n=1). There was an increase in RhoA expression in the Pyrintegrin treated Min6 cells versus the untreated Min6 cells.
-
Biomed Pharmacother
Triptolide attenuates pulmonary fibrosis by inhibiting fibrotic extracellular matrix remodeling mediated by MMPs/LOX/integrin. [Abstract]2023 Oct:166:115394. PMID: 37660647
Pyrintegrin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Oct:166:115394. [Abstract]
Representative image and quantitative analysis of cell aggregation cultured in conditioned matrix. Pyrintegrin (1 μM) reversed the inhibitory effect of Triptolide on MF-CM-induced cell aggregation.
Pyrintegrin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Oct:166:115394. [Abstract]
The activity of LOX and MMP3 in the cell culture supernatants of lung fibroblasts cultured in conditioned matrix. Pyrintegrin (1 μM) offset the suppressive effect of Triptolide on LOX and MMP3 activities in the MF-CM group.
Pyrintegrin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Oct:166:115394. [Abstract]
Representative immunofluorescence staining of α-SMA, collagen I and fibronectin in the lung fibroblasts retrieved from conditioned matrix. Pyrintegrin (1 μM) partly reversed the inhibitory effect of Triptolide on MF-CM-induced fibrotic marker expression.
용액&용해도
DMSO : 250 mg/mL (553.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shah BS, et al. Pyrintegrin Induces Soft Tissue Formation by Transplanted or Endogenous Cells. Sci Rep. 2017 Jan 27;7:36402. [Content Brief]
[2]. Lee HW, et al. A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules. J Am Soc Nephrol. 2015 Nov;26(11):2741-52. [Content Brief]
[3]. Xu Y, et al. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8129-34. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2146 mL | 11.0732 mL | 22.1464 mL | 55.3661 mL |
| 5 mM | 0.4429 mL | 2.2146 mL | 4.4293 mL | 11.0732 mL | |
| 10 mM | 0.2215 mL | 1.1073 mL | 2.2146 mL | 5.5366 mL | |
| 15 mM | 0.1476 mL | 0.7382 mL | 1.4764 mL | 3.6911 mL | |
| 20 mM | 0.1107 mL | 0.5537 mL | 1.1073 mL | 2.7683 mL | |
| 25 mM | 0.0886 mL | 0.4429 mL | 0.8859 mL | 2.2146 mL | |
| 30 mM | 0.0738 mL | 0.3691 mL | 0.7382 mL | 1.8455 mL | |
| 40 mM | 0.0554 mL | 0.2768 mL | 0.5537 mL | 1.3842 mL | |
| 50 mM | 0.0443 mL | 0.2215 mL | 0.4429 mL | 1.1073 mL | |
| 60 mM | 0.0369 mL | 0.1846 mL | 0.3691 mL | 0.9228 mL | |
| 80 mM | 0.0277 mL | 0.1384 mL | 0.2768 mL | 0.6921 mL | |
| 100 mM | 0.0221 mL | 0.1107 mL | 0.2215 mL | 0.5537 mL |
Pyrintegrin Related Classifications
HY-13306 Related Classifications
Powered by Bioz